AgingResearch.NewsJoin free

AskBio

Part of Bayer

CompanyUnited StatesFounded 2019

Wikidata

AskBio develops 2 assets, the furthest in phase 2 (AAV2-GDNF in Parkinson's disease). Mostly gene therapy acting on GDNF and GAA; based in the United States, founded in 2019.

2
Assets
Furthest stage
Phase 2
2
Trials
2
Signals

Pipeline

2

  • AAV2-GDNF

    AAV2 vector encoding GDNF delivered to the putamen for neurotrophic support

    Phase 2, Gene therapy, GDNF, Parkinson's disease

  • AB-1009

    Delivers a functional GAA gene to restore acid alpha-glucosidase activity and reduce lysosomal glycogen accumulation.

    Phase 1, Gene therapy, GAA, LOPD, Pompe disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Signals3
  • Similar companies6

Intelligence